CEL-SCI (STU:LSR) OCF Margin %: 0.00% (As of Mar. 2026)


STU:LSR CEL-SCI Corp STU:LSR
23 GF Score
Price €5.58
! 2 Warning Signs
View Full Analysis

What is CEL-SCI OCF Margin %?

CEL-SCI STU:LSR 23 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:LSR with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, CEL-SCI ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. CEL-SCI's Cash Flow from Operations for the three months ended in Mar. 2026 was €-3.48 Mil. CEL-SCI's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, CEL-SCI's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, CEL-SCI's current OCF Yield % is -97.80%.

The historical rank and industry rank for CEL-SCI's OCF Margin % or its related term are showing as below:


STU:LSR's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

CEL-SCI OCF Margin % Related Terms

CEL-SCI OCF Margin % Historical Data

* Premium members only.

The historical data trend for CEL-SCI's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CEL-SCI OCF Margin % Chart

CEL-SCI Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CEL-SCI Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:LSR
23GF Score
CEL-SCI Corp STU:LSR
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CEL-SCI OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

CEL-SCI's OCF Margin for the fiscal year that ended in Sep. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=-14.586/0
= %

CEL-SCI's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.479/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
CEL-SCI (STU:LSR) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on CEL-SCI and its competitors. According to the industry distribution chart, CEL-SCI ranks #999999 out of 959 companies in the Biotechnology industry.
Is CEL-SCI's OCF Margin % too high?
CEL-SCI's current OCF Margin % is 0.00%. Based on the distribution chart, CEL-SCI ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CEL-SCI has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does CEL-SCI's OCF Margin % compare to TRAW and QNCX?
According to the Biotechnology industry distribution chart, CEL-SCI ranks #999999 out of 959 companies for OCF Margin %. This places CEL-SCI in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on CEL-SCI and its competitors. CEL-SCI's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CEL-SCI stock overvalued right now?
CEL-SCI (STU:LSR) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. CEL-SCI's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For CEL-SCI (STU:LSR), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CEL-SCI Business Description

Other Exchanges CVM:USALSR:Germany
Address 8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
23GF Score

Get the complete analysis for STU:LSR

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.58
Price